New Models for Testing Parkinson’s Disease Immune-based Drugs

A team of researchers from the Perelman School of Medicine at the University of Pennsylvania has demonstrated that immunotherapy with specifically targeted antibodies may block the development and spread of Parkinson’s disease (PD) in the brain. Recently reported in Cell Reports, the study demonstrates that the researchers prevented the development of pathology and also reversed some of the effects of already-existing disease by intercepting the distorted and misfolded alpha-synuclein (α-syn) proteins that enter and propagate in neurons. The animal study shows promise in developing new therapies for PD. To learn more about the study, click here.